Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
Get Instant Summarized Text (Gist) The FDA has approved Enhertu for treating adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval follows the ...
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
Growth is expected to be supported by ENHERTU's continued expansion. Profit attributable to owners of the company for FY2024 was revised upward by ¥15 billion to ¥240 billion, driven by improved ...
With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under the brand name Enhertu) emerged as the highest-selling new drug brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results